Retina. 2025 Jun 2. doi: 10.1097/IAE.0000000000004542. Online ahead of print.
ABSTRACT
PURPOSE: to evaluate the effectiveness and safety of the fluocinolone acetonide implant (0.2 µg/day FAc, ILUVIEN®) in macular edema due to retinal amyloid angiopathy (RAA) in patients with hereditary transthyretin amyloidosis associated with the V30M mutation (ATTRV30M).
METHODS: retrospective observational case series of ATTRV30M patients’ eyes treated with the implant for macular edema, from January 2010 to December 2019. Best corrected visual acuity (BCVA), central foveal thickness (CFT) and intraocular pressure (IOP) were measured at baseline, at 1 week, and at months 1, 3, 6, and 12.
RESULTS: fifteen eyes of 15 ATTRV30M patients with FAc implants were included. All patients had already received a liver transplant. All had already been submitted to cataract surgery, 87% had an Ahmed valve implant and 80% were vitrectomized due to vitreous amyloidosis. A statistically significant improvement in BCVA and in CFT at all time points was found compared to baseline. There was no statistically significant difference in IOP during the follow-up.
CONCLUSIONS: patients with macular edema due to RAA treated with the FAc implant showed sustained increased functional results and anatomical improvement compared to baseline.
PMID:40456135 | DOI:10.1097/IAE.0000000000004542
